Concise Prescribing Info
Clindamycin (cap: HCl; inj: phosphate)
Upper resp tract (eg, chronic or recurrent tonsillitis, pharyngitis, sinusitis, otitis media & scarlet fever) & lower resp tract (eg, bacterial bronchitis, pneumonia, empyema, lung abscess) infections; difficult to treat skin & soft tissue infections (eg, acne, furunculosis), cellulitis), impetigo, abscesses, wound infections, erysipelas, nail wall infections); bone & joint infections (eg, osteomyelitis & septic arthritis); gynaecological infections (eg, endometritis, tubo-ovarian abscess, salpingitis, infections of the cervical area & inflammatory diseases of the pelvic area in combination w/ antibiotic effective against gm -ve aerobic bacteria); intra-abdominal infections (eg, peritonitis & abdominal abscess in combination w/ antibiotic effective against gm -ve aerobic bacteria; dental infections (eg, periodontal abscess & periodontitis). As monotherapy for cervicitis caused by Chlamydia trachomatis.
Dosage/Direction for Use
Cap Adult, elderly & adolescent >14 yr 600-1,800 mg/day in 3-4 equal divided doses. Childn & adolescent 8-25 mg/kg/day. Infections due to β-haemolytic strep Duration of treatment: At least 10 days. IM/IV Adult Serious infection 600-1,200 mg/day divided in 2-4 equal doses. More severe infection 1,200-2,700 mg/day divided in 2-4 equal doses. Infuse over at least 10-60 min. Childn >1 mth Serious infection 15-25 mg/kg/day in 3-4 equal doses. More severe infection 25-40 mg/kg/day in 3-4 equal doses. Neonate <1 mth 15-20 mg/kg/day in 3-4 equal doses.
May be taken with or without food: Take w/ a full glass of water to avoid oesophageal irritation.
Hypersensitivity to clindamycin or lincomycin. Inj: Treatment of meningitis; nonbacterial upper resp or mild bacterial infections. Lactation.
Special Precautions
Pregnancy. Should not be taken during lactation. Cap: Severe hypersensitivity reactions including severe skin reactions eg, drug reaction w/ eosinophilia & systemic symptoms, Stevens-Johnson syndrome, toxic epidermal necrolysis & acute generalised exanthematous pustulosis. Patients w/ existing penicillin allergy. Consider diagnosis of Clostridium difficile-associated diarrhea in patients who present diarrhea subsequent to the administration of antibacterials. History of GI disease especially colitis. Not to be used in the treatment of meningitis. Overgrowth of non-susceptible organisms particularly yeasts. Renal & hepatic function tests should be performed in prolonged therapy. Inj: Do not inj IV undiluted as a bolus. Patients w/ history of colitis, renal or hepatic disease; dysphagia. Atopic individuals. Neonate, immature fetus. Elderly.
Adverse Reactions
Cap: Pseudomembranous colitis; eosinophilia; diarrhea; maculopapular rash; abnormal liver function test. Inj: Local & hypersensitivity reactions; GI, skin, hepatic, renal, musculoskeletal, hematopoietic & nervous system effects; shock.
Drug Interactions
May enhance action of neuromuscular blocking agents. In vitro antagonism w/ erythromycin. May reduce clearance w/ CYP3A4 & CYP3A5 inhibitors. May increase clearance w/ CYP3A4 & CYP3A5 inducers. Cross-resistance w/ lincomycin. Increased PT/INR &/or bleeding w/ vit K antagonist (eg, warfarin, acenocoumarol & fluindione).
MIMS Class
Other Antibiotics
ATC Classification
J01FF01 - clindamycin ; Belongs to the class of lincosamides. Used in the systemic treatment of infections.
Peldacyn cap 300 mg
30's (P410.71/box)
Peldacyn soln for inj 150 mg/mL
2 mL x 10 × 1's (P298.39/ampoule, P2,983.93/box);4 mL x 10 × 1's (P447.59/ampoule, P4,475.67/box)
/philippines/image/info/peldacyn soln for inj 150 mg-ml/150 mg-ml x 4 ml?id=83274eec-3dc3-4d6e-b1f5-a51d00ed33d6
/philippines/image/info/peldacyn soln for inj 150 mg-ml/150 mg-ml x 2 ml?id=17a713b0-3120-4532-b44a-a51d00ed33d6
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in